ClinicalTrials.gg

Blood Coagulation Disorders clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 148 studies for Blood Coagulation Disorders across more than 10 countries. 16 are recruiting or about to start. 60 of them are mainly about Blood Coagulation Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 15 narrower conditions too, such as Hemophilia A: 2,163 studies, 438 open.

Status

Completed
87
Status unknown
23
Recruiting
13
Terminated
11
Withdrawn
8
Active, not recruiting
3

Phase

Phase 3
22
Phase 2
17
Phase 1
17
Phase 4
14
Early Phase 1
1

Where

United States
55
United Kingdom
23
France
22
Spain
19
Italy
18
Germany
18

Who develops what

Add Blood Coagulation Disorders to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 3 companies, 1 with this as their studies’ main aim; 3 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
cryoprecipitateRecent, limited
Evidence
  • NCT06617897 · CSL Limited · Phase 3 · live · comparator · “Cryoprecipitate” · registered Sep 2024
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Immunoglobulins, Intravenous · Kedrion S.p.A. · Phase 3 named, not the main aimNCT07059000 A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) — primary endpoint: Rate of subjects with response (R) · 40 enrolled
  • Mar 2027 est.efanesoctocog alfa · Swedish Orphan Biovitrum · Phase 3 named, not the main aimNCT06716814 Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa — primary endpoint: Number of injections to treat a bleeding episode · 89 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Blood Coagulation Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3

Coming up

8studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 13 Blood Coagulation Disorders studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger. 6 (46%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (23%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
103 (23%)3 (23%)
1813 (100%)13 (100%)
3013 (100%)13 (100%)
4013 (100%)13 (100%)
5013 (100%)13 (100%)
6512 (92%)12 (92%)
7510 (77%)10 (77%)
859 (69%)9 (69%)

Across all 148 studies, recruiting or not: 27% stop at 75 or younger and 22% at 65; 28% take children; 4% are for women only and 19% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Blood Coagulation Disorders studies take

Of 29 observational studies under Blood Coagulation Disorders, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational33 mo20–59 · 29 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 148. Browse all 148 → or search them.